ArticleProceedings of the National Academy of Sciences of the United States of America2010
Dynamic antibody responses to the Mycobacterium tuberculosis proteome.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
156 citing papers in PubMed, 2 syntheses or guidelines pooled it, 248 citations in OpenAlex.
- Anti-PGL-1 Positivity as a Risk Marker for the Development of Leprosy among Contacts of Leprosy Cases: Systematic Review and Meta-analysis.PLoS neglected tropical diseases · 2016Pooled it
- Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis.Clinical and vaccine immunology : CVI · 2011Pooled it
- Latently and uninfected healthcare workers exposed to TB make protective antibodies againstProceedings of the National Academy of Sciences of the United States of America · 2017Trial
- O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection.PLoS pathogens · 2013Trial
- ESAT-6-derived lipopeptide-based mucosal vaccine elicits distinct humoral immune responses concomitant with a reduction inEmerging microbes & infections · 2026Article
- Styrene Maleic Acid Lipid Particles Prepared from Mycobacterium tuberculosis Plasma Membrane can Potentially Induce Innate and Adaptive Immune Responses in Healthy Individuals of a Tuberculosis Hyperendemic Region.Current microbiology · 2026Article
- Blinded trial of multiplex serodiagnostic test in India for diverse forms of active tuberculosis.Microbiology spectrum · 2026Article
- Immunodominant Tuberculosis Antigens Recognized by Human CD4Cold Spring Harbor perspectives in medicine · 2026Article
- Revisiting the Antigen 85 Complex as a Target for Functional Antibody-Based Strategies AgainstMicroorganisms · 2026Review
- Commentary: A proteome-wide atlas of humoral immunity toFrontiers in immunology · 2026Article
- Comprehensive Approaches to Protein Detection and Analysis in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Review
- Immunoproteomics: The Evolution from Classical Methods to Emerging Techniques.Methods in molecular biology (Clifton, N.J.) · 2026Review
- A proteome-wide atlas of humoral immunity toFrontiers in immunology · 2026Article
- Identification and serological characterization of MtbAg1073, a conserved Mycobacterium tuberculosis complex antigen recognized in active tuberculosis.Environmental health and preventive medicine · 2026Article
- ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteria.Cell reports · 2025Article
- Culture conditions impact the protein expression profile of Mycobacterium bovis BCG strains Moreau and Pasteur.BMC microbiology · 2025Article
- An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development.Journal of virology · 2025Article
- Sera contributing to mycobacterial growth restrictioniScience · 2025Article
- Different antibody isotypes against tuberculosis: what we know and what we need to know.Frontiers in immunology · 2025Review
- B Cell and Antibody Responses in Bovine Tuberculosis.Antibodies (Basel, Switzerland) · 2024Review
96 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considerable effort has been directed toward controlling tuberculosis, which kills almost two million people yearly. High on the research agenda is the discovery of biomarkers of active tuberculosis (TB) for diagnosis and for monitoring treatment outcome. Rational biomarker discovery requires understanding host-pathogen interactions leading to biomarker expression. Here we report a systems immunology approach integrating clinical data and bacterial metabolic and regulatory information with high-throughput detection in human serum of antibodies to the entire Mycobacterium tuberculosis proteome. Sera from worldwide TB suspects recognized approximately 10% of the bacterial proteome. This result defines the M. tuberculosis immunoproteome, which is rich in membrane-associated and extracellular proteins. Additional analyses revealed that during active tuberculosis (i) antibody responses focused on an approximately 0.5% of the proteome enriched for extracellular proteins, (ii) relative target preference varied among patients, and (iii) responses correlated with bacillary burden. These results indicate that the B cell response tracks the evolution of infection and the pathogen burden and replicative state and suggest functions associated with B cell-rich foci seen in tuberculous lung granulomas. Our integrated proteome-scale approach is applicable to other chronic infections characterized by diverse antibody target recognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.